Splenectomy and risk of blast transformation in myelofibrosis with myeloid metaplasia. Italian Cooperative Study Group on Myeloid with Myeloid Metaplasia.

An unexpectedly high incidence of blast transformation after splenectomy has been reported in patients with myelofibrosis with myeloid metaplasia. However, whether this was associated with spleen removal after adjustment for risk factors was not determined. We conducted a multicenter historical cohort study of patients with myelofibrosis with myeloid metaplasia diagnosed from January 1970 through January 1994. A total of 549 patients (325 men and 224 women from 22 to 92 years of age; median age, 63 years) were included in the final data set. The Cox's proportional-hazards model was used to identify factors associated with blast transformation and death. To further adjust for factors related to spleen removal assignment, a propensity score for splenectomy was estimated using recursive-partitioning analysis. Blast transformation developed in 78 patients (14.2%). Patients who underwent splenectomy developed more blast transformations than those who were not splenectomized (23 of 87 [26.4%] v 55 of 462 [11.9%]; P < .001). The cumulative incidence of blast transformation 12 years after diagnosis was 27.0% in nonsplenectomized patients and 55.0% in splenectomized ones (P = . 01). The risk factors independently predictive of blast transformation included prior splenectomy (relative risk = 2.61), platelet count less than 100 x 10(9)/L at diagnosis (relative risk = 2.45), and the presence of blasts in peripheral blood at diagnosis (relative risk = 2.31). The relative risk of blast transformation in splenectomized patients increased from 2.2 at 48 months from diagnosis to 14.3 at 12 years. Patients with the same propensity score for splenectomy showed a higher risk for blast transformation on the basis of having undergone splenectomy (P = .02). In conclusion, the risk of blast transformation is significantly increased in subjects who underwent splenectomy and appears to be independent of factors related to spleen removal assignment.

[1]  J. Laszlo Myeloproliferative disorders (MPD): myelofibrosis, myelosclerosis, extramedullary hematopoiesis, undifferentiated MPD, and hemorrhagic thrombocythemia. , 1975, Seminars in hematology.

[2]  A. Hart,et al.  SPLENECTOMY IN HODGKIN'S DISEASE AND SECOND LEUKAEMIAS , 1987, The Lancet.

[3]  L. Robison,et al.  Breast cancer and other second neoplasms after childhood Hodgkin's disease. , 1996, The New England journal of medicine.

[4]  W. Haenszel,et al.  Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.

[5]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[6]  J. Bosq,et al.  Second primary cancers in patients continuously disease-free from Hodgkin's disease: a protective role for the spleen? , 1994, Blood.

[7]  A. Hart,et al.  Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  S. Quaglini,et al.  Splenectomy for patients with myelofibrosis with myeloid metaplasia: pretreatment variables and outcome prediction. , 1993, Leukemia.

[9]  R. Smart,et al.  Prognostic Factors in Myelofibrosis , 1982, Pathology.

[10]  David A. Schoenfeld,et al.  Chi-squared goodness-of-fit tests for the proportional hazards regression model , 1980 .

[11]  A. Varki,et al.  The Syndrome of Idiopathic Myelofibrosis: A CLINICOPATHOLOGIC REVIEW WITH EMPHASIS ON THE PROGNOSTIC VARIABLES PREDICTING SURVIVAL , 1983, Medicine.

[12]  L. Elveback,et al.  Agnogenic myeloid metaplasia. Natural history and treatment. , 1967, Archives of internal medicine.

[13]  Y. Najean,et al.  Risks and benefits of splenectomy in myelofibrosis: an analysis of 39 cases. , 1994, Nouvelle revue francaise d'hematologie.

[14]  H. Adami,et al.  Risk of cancer following splenectomy , 1996, International journal of cancer.

[15]  P. Voûte,et al.  Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. , 2006, Medical and pediatric oncology.

[16]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[17]  M. Cazzola,et al.  Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity , 1983, Cancer.

[18]  J. Fraumeni,et al.  SPLENECTOMY AND SUBSEQUENT MORTALITY IN VETERANS OF THE 1939-45 WAR , 1977, The Lancet.

[19]  M. Block,et al.  The natural history of agnogenic myeloid metaplasia (AMM) and a critical evaluation of its relationship with the myeloproliferative syndrome. , 1971, Medicine.

[20]  J. Fermanian,et al.  Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Tefferi,et al.  Agnogenic myeloid metaplasia. , 1995, Seminars in oncology.

[22]  A. Hagenbeek,et al.  Second cancer risk following Hodgkin's disease: a 20-year follow-up study. , 1994, Journal of Clinical Oncology.

[23]  S. Pileri,et al.  Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients , 1990, British journal of haematology.

[24]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[25]  J. Pitcock,et al.  A clinical and pathological study of seventy cases of myelofibrosis. , 1962, Annals of internal medicine.

[26]  A. Tichelli,et al.  Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party. , 1993, The New England journal of medicine.

[27]  S. Emery,et al.  Natural History and Treatment , 1997 .

[28]  B. Bouroncle,et al.  MYELOFIBROSIS CLINICAL, HEMATOLOGIC AND PATHOLOGIC STUDY OF 110 PATIENTS , 1962, The American journal of the medical sciences.

[29]  M. Laval-Jeantet,et al.  Prognosis of myeloid metaplasia with myelofibrosis. , 1976, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[30]  D. Arthur,et al.  Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features. , 1984, American journal of clinical pathology.

[31]  S. Lewis,et al.  Erythroid Hypoplasia in Myelofibrosis: a Feature Associated with Blastic Transformation , 1977, British journal of haematology.

[32]  M. Hudson,et al.  Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Zimmerman,et al.  Hodgkin's disease: study of treatment intensities and incidences of second malignancies. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  N. Day,et al.  Leukemia following Hodgkin's disease. , 1990, The New England journal of medicine.

[35]  W. Moloney,et al.  Reduction of leukemia incidence following splenectomy in the rat. , 1973, Cancer research.

[36]  A. Hagenbeek,et al.  Subsequent development of acute non‐lymphocytic leukemia in patients treated for Hodgkin's disease , 1988, International journal of cancer.

[37]  P. Gobbi,et al.  Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  S. Kvaløy,et al.  Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  A. Tefferi Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[40]  L. Fisher,et al.  Prognostic models and the propensity score. , 1995, International journal of epidemiology.

[41]  M. Block Agnogenic myeloid metaplasia. , 1974, Revista brasileira de pesquisas medicas e biologicas.

[42]  D.,et al.  Regression Models and Life-Tables , 2022 .

[43]  K. Nason-Burchenal,et al.  Involvement of the spleen in preleukemic development of a murine retrovirus-induced promonocytic leukemia. , 1992, Cancer research.